Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Renal Failure: Dose Adjustments

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...

Hemodialysis II: Procedure and Complications

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

NICU to neighborhood: structural drivers shape health inequities for preterm infants.

Pediatric research·2026

Same author

Renin-Angiotensin-Aldosterone System Inhibition Exacerbates Anemia in Sickle Cell Disease.

Blood·2026

Same author

More disease-modifying therapies for sickle cell disease: Are small molecules and drug repurposing the way forward?

Seminars in hematology·2026

Same author

A 2-year randomized trial of pitavastatin calcium vs placebo to treat combined dyslipidemia in adolescents with overweight and obesity.

Journal of clinical lipidology·2026

Same author

I-STRONG: an integrative, multicomponent treatment approach for chronic pain in pediatric sickle cell disease.

Blood advances·2026

Same author

Clinical Practice Patterns for Discussing Hydroxyurea Initiation With Families of Children With Sickle Cell Disease.

Pediatric blood & cancer·2026

Search research articles

Related Experiment Video

Updated: Jun 4, 2026

Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis

Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis

Published on: October 2, 2020

Renal dysfunction in patients with thalassaemia.

Charles T Quinn¹, Valerie L Johnson, Hae-Young Kim

¹U.T. Southwestern Medical Center, Dallas, TX, USA. charles.quinn@cchmc.org

British Journal of Haematology

|February 22, 2011

Summary

Kidney abnormalities like hyperfiltration and hypercalciuria are common in thalassemia patients. Regular blood transfusions are linked to lower kidney function but increased hypercalciuria, impacting treatment decisions.

More Related Videos

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Related Experiment Videos

Last Updated: Jun 4, 2026

Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis

Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis

Published on: October 2, 2020

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Area of Science:

Nephrology
Hematology
Internal Medicine

Background:

Thalassemia's impact on kidney function is poorly understood.
Iron chelators, like deferasirox, can cause kidney damage, necessitating knowledge of baseline renal health in thalassemia patients.

Purpose of the Study:

To determine the prevalence and predictors of kidney function abnormalities in thalassemia patients.
To assess renal function before widespread use of deferasirox.

Main Methods:

Utilized 24-hour urine collections to measure creatinine clearance, urine calcium-to-creatinine ratio, and urinary β(2)-microglobulin, albumin, and protein.
Employed multivariate modeling to identify predictors of renal dysfunction.

Main Results:

One-third of non-regularly transfused patients exhibited high creatinine clearance (hyperfiltration).
Regular transfusions correlated with decreased creatinine clearance and increased hypercalciuria.
Albuminuria was prevalent in over half of patients, independent of transfusion status.

Conclusions:

Renal hyperfiltration, hypercalciuria, and albuminuria are frequent in thalassemia.
Transfusion intensity influences kidney function parameters, requiring further investigation.
Understanding baseline renal dysfunction is crucial for managing iron chelation therapy in thalassemia.